NCT01022762View on ClinicalTrials.gov

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

PHASE4CompletedINTERVENTIONAL

Enrollment

440

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

Individually adjusted dose for 16 weeks

DRUG

gliclazide

Individually adjusted dose for 16 weeks

Trial Locations (1)

200025

Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY